The stock market has been pulled aggressively in both directions in 2021, but the moves are relatively tame compared to the wild ride of Vaxart (VXRT) stock. Toward the end of January, shares more than doubled in less than a week due to the formidable pairing of high short interest and the hope of positive Phase 1 results for the company’s oral Covid-19 vaccine candidate VXA-CoV-1. In the end, the stock took a 60% hammering, after Vaxart’s offering failed to deliver evidence of neutralizing antibodies in the study’s participants. The results, however, haven’t deterred Vaxart from progressing its Covid-19 program further.